Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
06/2003
06/10/2003US6576236 Contacting T cell which expresses cytokine receptor gamma chain with anti-gamma chain antibody which binds to and transduces signal via gamma chain such that T cell responsiveness is stimulated
06/10/2003CA2413024A1 Antipyretic preparation containing xylitol
06/10/2003CA2303577C Qt dispersion and heart rate variability improvement with crf antagonists to prevent sudden death
06/10/2003CA2225286C A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof
06/10/2003CA2204437C Novel compositions based on a synergistic combination of one or more vrd ligands and retinoids
06/06/2003CA2413479A1 Kit for reducing aching
06/05/2003WO2003046581A2 Methods for diagnosis and treatment of epithelial-derived cancers,such as colorectal cancers and kidney cancers
06/05/2003WO2003046580A1 Assay for screening candidate drugs for the treatment of inflammatory diseases
06/05/2003WO2003046578A2 Method for the assessment and prognosis of sarcoidosis
06/05/2003WO2003046576A1 Fibrinogen biopolymer marker and its use for the screening of type ii diabetes
06/05/2003WO2003046575A1 Biopolymer marker indicative of normal human
06/05/2003WO2003046574A2 Complement c3 precursor biopolymer markers indicative of insulin resistance
06/05/2003WO2003046570A2 Glycoprotein and apolipoprotein biopolymer markers predictive of alzheimers disease
06/05/2003WO2003046564A2 Protein biopolymer markers predictive of alzheimers disease
06/05/2003WO2003046556A2 Globin biopolymer markers indicative of insulin resistance
06/05/2003WO2003046552A2 Screening method for compounds that modulate neuronal activity
06/05/2003WO2003046192A1 Antibiotics ge 81112 factors a, b, b1, pharmaceutically acceptable salts and compositions, and use thereof
06/05/2003WO2003046180A2 Human cdnas and proteins and uses thereof
06/05/2003WO2003046171A1 A method for combined sequential agent delivery and electroporation for cell structures and use thereof
06/05/2003WO2003046170A1 A method for combined parallel agent delivery and electroporation for cell structures and use thereof
06/05/2003WO2003046010A1 Inter alpha trypsin inhibitor biopolymer markers indicative of insulin resistance
06/05/2003WO2003046008A1 Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma
06/05/2003WO2003046007A2 Treatment of micro-organism infection
06/05/2003WO2003045999A2 Human vanilloid receptor protein and polynucleotide sequence encoding same
06/05/2003WO2003045993A2 Protein biopolymer markers predictive of type ii diabetes
06/05/2003WO2003045991A2 Complement c3 precursor biopolymer markers predictive of alzheimers disease
06/05/2003WO2003045984A2 Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance
06/05/2003WO2003045983A1 Apolipoprotein biopolymer markers predictive of type ii diabetes
06/05/2003WO2003045977A2 Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes
06/05/2003WO2003045965A2 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
06/05/2003WO2003045946A1 5-(4-(2-(n-methyl-n-(2-pyridil) amino) ethoxy) benzyl) thiazolidine-2, 4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient
06/05/2003WO2003045925A1 1,2,4-triazole derivatives containing a sulphamate group as aromatase inhibitors
06/05/2003WO2003045910A2 Diagnosis of endothelial dysfunction by nitric oxide bioactivity index
06/05/2003WO2003045908A2 Method for controlling angiogenesis in animals
06/05/2003WO2003045582A1 Metallic structures incorporating bioactive materials and methods for creating the same
06/05/2003WO2003045523A2 Therapeutic coating for an intravascular implant
06/05/2003WO2003045459A1 Milk protein biofilm and uses thereof
06/05/2003WO2003045456A1 Process for coating a surface of a stent
06/05/2003WO2003045438A1 Increasing electro-gene transfer of nucleic acid molecules into host tissue
06/05/2003WO2003045434A2 Endothelin antagonists ina method and composition for potentiating an opiate analgesic
06/05/2003WO2003045431A2 Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist
06/05/2003WO2003045429A2 Anti-t cell immunotoxin fusion protein and its therapeutic use
06/05/2003WO2003045425A1 Muscle transcription factors
06/05/2003WO2003045405A2 Lactic acid bacteria and their use for treating and preventing cancer
06/05/2003WO2003045400A1 Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
06/05/2003WO2003045383A1 Use of ppar activators for the treatment of pulmonary fibrosis
06/05/2003WO2003045382A1 Therapeutic compounds for treating dyslipidemic conditions
06/05/2003WO2003045379A1 Hydrazonopyrazole derivatives and their use as therapeutics
06/05/2003WO2003045373A1 Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease
06/05/2003WO2003045371A1 Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
06/05/2003WO2003045366A1 Treatment of wounds and compositions employed
06/05/2003WO2003045356A1 Pharmaceutical dosage form with multiple coatings
06/05/2003WO2003045338A1 Compositions comprising phenyl-glycine derivatives
06/05/2003WO2003045334A2 Methods and compositions for ameliorating the undesirable effects of chemotherapy
06/05/2003WO2003045333A2 Treatment of hyperproliferative diseases using active vitamin d analogues
06/05/2003WO2003045332A2 Methods and compositions for treating lesions of the respiratory epithelium
06/05/2003WO2003045319A2 Targeted therapeutics and uses thereof
06/05/2003WO2003045317A2 Therapeutic protein and treatments
06/05/2003WO2003045274A2 Thermopolymer composition and related methods
06/05/2003WO2003045230A2 Novel compositions and methods for cancer
06/05/2003WO2003045229A2 Methods and compositions for treating cancer
06/05/2003WO2003045153A1 Combination bacteriolytic therapy for the treatment of tumors
06/05/2003WO2003045136A1 Disruption of the prostaglandin e synthase 2 gene
06/05/2003WO2003029418A3 Proliferation and differentiation of stem cells using extracellular matrix and other molecules
06/05/2003WO2003020106A3 Composite staple for completing an anastomosis
06/05/2003WO2002102306A3 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
06/05/2003WO2002099118A3 Method of identifying a polymorphism in cyp2d6
06/05/2003WO2002081665A3 Implantation serine proteinases
06/05/2003WO2002077261A3 Human potassium channel
06/05/2003WO2002074924A3 Method for measuring serine palmitoyltransferase in mammalian tissue and use thereof
06/05/2003WO2002069949A3 Combination therapy for reduction of toxycity of chemotherapeutic agents
06/05/2003WO2002068548A3 Use of erss-selective ligands for regulating fertility and compounds useful therefore
06/05/2003WO2002062841A3 Secreted proteins
06/05/2003WO2002060485A3 Use of immunoregulatory antibodies in the treatment of neoplastic disorders
06/05/2003WO2002046230A3 G-protein coupled receptors
06/05/2003WO2002042330A3 Cystoskeleton-associated proteins
06/05/2003WO2002036075A3 Small molecule compositions for binding to hsp90
06/05/2003US20030106085 Disruption of the prostaglandin E synthase 2 gene
06/05/2003US20030105333 RXR activating molecules
06/05/2003US20030105330 Synthesis of epothilones, intermediates thereto and analogues thereof
06/05/2003US20030105318 G-protein transmembrane domain; protein synthesis inhibitor; neurotransmitter
06/05/2003US20030105292 Continously induced g-protein coupled receptors; membrane binding assays
06/05/2003US20030105285 Odorant receptors
06/05/2003US20030105165 Gap junctions and EDHF
06/05/2003US20030105162 Method for treating bronchial constriction and bronchospasm
06/05/2003US20030105161 Analgesics; antiinflamamtory agents
06/05/2003US20030105144 Celecoxib dissolving in polyethylene glycol; antiinflammatory agents, osteoporosis, respiratory system disorders, antitumor agents, analgesics
06/05/2003US20030105141 Mixture containing fatty acid and aromatic amine; administering by mouth; cyclooxygenase enzyme inhibitor
06/05/2003US20030105140 Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
06/05/2003US20030105138 Using carvedilol, or synergistic mixture thereof
06/05/2003US20030105126 Irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
06/05/2003US20030105122 Compounds for enhancing chemotherapy
06/05/2003US20030105114 Methods of treatment and kits comprising a growth hormone secretagogue
06/05/2003US20030105106 5-HT receptor ligands and uses thereof
06/05/2003US20030105094 For therapy of metabolic disorder, an eating disorder or diabetes
06/05/2003US20030105092 Prevention of loss and restoration of bone mass by certain prostaglandin agonists
06/05/2003US20030105090 For therapy of cancer, diabetes
06/05/2003US20030105085 Antagonists of MCP-1 function and methods of use thereof
06/05/2003US20030105051 Nucleic acid treatment of diseases or conditions related to levels of HER2
06/05/2003US20030105031 Administering therapeutically effective amount of one or more flavonoids and carrier for therapy of reactive and inflammatory dermatoses
1 ... 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 ... 1151